Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several cancers. While these immunotherapies have improved patient outcomes in many clinical settings, they bring accompanying risks of toxicity, specifically immune-related adverse events (irAEs). There is a need for...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Rajeev Sharma, Laura C Cappelli, Michelle Turner, Julie R Brahmer, Jarushka Naidoo, Paolo Antonio Ascierto, Igor Puzanov, Hamzah Abu-Sbeih, Jeffrey A Sosman, Marc S Ernstoff, Jill Brufsky, Mario E Lacouture, Douglas B Johnson, Lamya Hamad, Miguel-Angel Perales, Eric Hansen, David E Gerber, Frank B Cortazar, Gregory A Masters, Michele Nanni, Satish P Shanbhag, Dimitra Skondra
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMJ Publishing Group 2021-06-01
Colecção:	Journal for ImmunoTherapy of Cancer
Acesso em linha:	https://jitc.bmj.com/content/9/6/e002435.full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!